Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
Minoryx Therapeutics and Neuraxpharm Group’s Development of a New CNS Therapy in Europe
KAMAX’s Acquisition of a Stake in Galol
Baker McKenzie advised KAMAX on the deal. KAMAX executed the acquisition of a majority stake in the Spanish coating company Galol. KAMAX is a leading global...